Diagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025




Diagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study

Final study analysis will inform design of interventional clinical trial, initiating in 2026, assessing DIAG723, a first-in-class, disease modifying treatment designed specifically to address the underlying cause of HHT

WATERTOWN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, will present interim data from its natural history study, HHT IMPACT, for hereditary hemorrhagic telangiectasia (HHT) at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 6-9, 2025 in Orlando, Florida.

HHT is a rare disease in which abnormal blood vessel formation causes bleeding events that can be serious or life-threatening, and for which there are currently no approved therapies. Initiated in partnership with the leading patient advocacy organization, Cure HHT, HHT IMPACT is designed to characterize patient-reported outcomes in HHT, including epistaxis (nosebleed) frequency, severity, and duration, hematologic support, and quality of life (QoL), using a novel patient-reporting instrument, the “During My Day Diary,” as well as established assessment tools, such as Epistaxis Severity Score (ESS).

“The interim results from HHT IMPACT describe a patient population whose quality of life is deeply affected by HHT, with nearly two-thirds of participants reporting daily nosebleeds and nearly forty percent reporting multiple nosebleeds per day,” said John Lee, M.D., Ph.D., Chief Medical Officer of Diagonal Therapeutics. “Insights from this natural history study will inform the design of our first-in-human clinical trial of DIAG723, which will start enrolling mid-2026. With its unique receptor clustering mechanism, DIAG723 has the potential to prevent and reverse all manifestations and complications associated with HHT by directly addressing the root cause of the disease. We are grateful to all the individuals participating in this study and look forward to applying the valuable learnings toward advancing a much needed, disease-modifying treatment for this serious disease.”

HHT IMPACT enrolled 109 adult HHT patients with moderate-to-severe bleeding. The study implemented and validated the “During My Day Diary,” which captured the frequency, duration, and intensity of each epistaxis event. Results from the interim analysis confirm the significant burden of HHT:

• Majority of patients reported daily epistaxis, including a large proportion reporting several epistaxis events per day.
• Nearly half of the participants reported being anemic in the three months prior to enrollment.
• Participants averaged more than 20 nosebleeds per month and a mean duration of nearly 20 minutes per bleeding event.

The final analysis will be presented at a future scientific congress and will report on additional characterization of bleeding events and QoL assessments, with further evaluation of the impact HHT has on activities of daily living.

Details for the poster presentation are as follows:

Title: An interim assessment of bleeding events in a prospective natural history study of hereditary hemorrhagic telangiectasia patients using a validated bleeding scale and a novel daily reporting instrument
Presenter: John Lee, M.D., Ph.D., Chief Medical Officer, Diagonal Therapeutics
Poster ID: 2702
Poster Session: Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I
Location: OCCC – West Halls B3-B4
Poster Date & Time: Saturday, December 6, 5:30-7:30 pm EST

The poster will be available on the Diagonal website following the meeting.

About Hereditary Hemorrhagic Telangiectasia (HHT) 
HHT is a rare disease that affects more than 330,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss of function point mutations in members of the TGF-ß receptor superfamily complex create abnormal blood vessels that are fragile and susceptible to rupture and bleeding. These bleeding events drastically reduce quality of life, result in emergency visits and hospitalizations, and lead to chronic anemia, necessitating frequent iron infusions or red blood cell transfusions in many patients. Solid organ arteriovenous malformations, if left untreated, are at risk of rupturing, resulting in lung and brain hemorrhage, stroke, heart failure, and death.

About HHT IMPACT Natural History Study
HHT IMPACT is a first-of-its-kind non-interventional, observational, longitudinal evaluation characterizing the variability of HHT patient-reported outcomes, including nosebleeds, hematologic support, and quality of life. The study is fully enrolled, and complete data are anticipated in 2026. To learn more about the HHT Impact study in partnership with Cure HHT, please visit: https://curehht.org/hhtimpact/.

About DIAG723
‍DIAG723 is a bispecific antibody designed to address HHT and PAH, in which dysregulated ALK1 signaling in endothelial cells drives the formation of fragile arteriovenous malformations or vascular hyperproliferation, respectively. DIAG723 restores signaling lost due to mutations that impair receptor function. In multiple HHT preclinical studies, DIAG723 prevented and reversed arteriovenous malformations and anemia – a hallmark of HHT that can cause a host of bleeding-related complications in various organs. DIAG723 was also found to restore signaling in multiple HHT patient donor samples. In preclinical models of PAH, DIAG723 prevented disease development and cardiac remodeling, and improved hemodynamics. DIAG723 also restored normal signaling in pulmonary microvascular endothelial cells derived from multiple PAH donors. DIAG723 has received orphan drug designation from the US FDA and the EMA for the treatment of HHT.

About Diagonal Therapeutics
Diagonal Therapeutics is a biotech company advancing novel disease-modifying clustering antibodies that repair dysregulated signaling implicated in a range of illnesses. The Company’s DIAGONAL Product Engine combines proprietary computational and experimental techniques to overcome historical challenges associated with antibody drug discovery and efficiently deliver optimized therapeutic assets. Diagonal’s pipeline comprises clustering antibodies designed to selectively address the underlying cause of disease across hematology, hepatology, and nephrology, offering the potential to deliver life-changing therapies for patients. For more information, please visit www.diagonaltx.com.

Media Contact
media@diagonaltx.com

Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact




Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) — Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio’s operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company’s operations or finances.

Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists to assist in the investigation and to help ensure the security of its systems. Precipio also took prompt steps to secure the environment, reset passwords company wide, and enhance monitoring and at this time, we are not seeing evidence of continued unauthorized access.

While the investigation remains ongoing, current findings indicate that an unauthorized third party accessed and downloaded certain historical files within the customer service folder. Initial investigation shows that the majority of these files contained previously used operational procedures, temperature logs, vendor invoices and similar historical information which poses no risk or damage to the company. No patient Social Security numbers, addresses, or other patient financial information was included. Additionally, no company proprietary or financial data was included in the folders that were breached.

We are pursuing a thorough investigation with top-tier cybersecurity partners, and although the review is ongoing, our current assessment strongly suggests that the incident was limited in scope and that our systems are stable.

Precipio maintains a comprehensive cybersecurity insurance policy and expects that costs associated with the investigation, forensic analysis, and related response efforts will be covered in accordance with policy terms. Based on the information available at this time the company does not anticipate any material impact to its operations, customers, patient care, or to its shareholders as a result of this incident.

The Company will provide further updates if and as appropriate.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523

ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer




ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark Bertagnolli as Chief Operating Officer. With this appointment, Bertagnolli will expand his leadership responsibilities beyond his current position as Chief Business Officer, including oversight of business development and strategic partnerships to accelerate the company’s growth as it expands the reach of its oncolytic virus pipeline.

“Mark has been a key partner in shaping ViroMissile’s strategy since joining the company, and his leadership has already played an essential role in advancing our mission,” said Nanhai George Chen, PhD, CEO and founder of ViroMissile. “As we advance our IDOV platform and lead programs into further clinical investigation, Mark’s experience and expanded leadership across business, finance, and strategic growth will be instrumental in shaping our next phase of growth.”

Bertagnolli brings decades of leadership across biotechnology, finance, and advanced engineering to his role at ViroMissile. He has served as Chief Business Officer since 2024 and as a member of the company’s Board of Directors. He previously founded Amitech Therapeutic Solutions and served as Chief Business Officer at Genelux, where he worked closely with ViroMissile founder Dr. Nanhai George Chen. Prior to that, Mark spent more than a decade in senior investment roles on Wall Street, including founding FrontPoint Partners’ global technology hedge fund and serving as a partner at Andor Capital Management. His private sector career began in the semiconductor industry with roles at Texas Instruments and Philips Semiconductor, following his service as a nuclear submarine officer in the U.S. Navy, where he earned a Nuclear Engineer designation from Naval Reactors. Mark holds a bachelor’s degree in aerospace engineering from the University of Michigan and is a NACD Certified Director.

Mark Bertagnolli added, “I’m honored to take on this expanded role at ViroMissile at this critical stage of growth. Our IDOV platform represents a true breakthrough in harnessing systemically delivered oncolytic viruses to attack tumors that are often resistant to current therapeutic modalities. The scientific progress the team has achieved is extraordinary, and I look forward to continuing working with them to potentially bring this innovation to patients and partners worldwide.”

ViroMissile’s IDOV™ platform is built on an engineered vaccinia virus optimized for intravenous delivery, tumor-selective replication, and immune activation. The platform enables body-wide targeting of solid tumors and represents a new frontier in systemic virotherapy.

About ViroMissile, Inc.
ViroMissile, Inc. is a cancer immunotherapy company harnessing a systemically delivered oncolytic virus that seeks and selectively destroy tumors throughout the body. As the first company to demonstrate effective intravenous tumor targeting with an oncolytic virus in humans, ViroMissile is leading a new era of viral immunotherapy that combines direct tumor killing with immune activation for durable responses in patients with advanced solid tumors. The company’s proprietary IDOV™ (Intravenously Deliverable Oncolytic Virus) platform is designed to extend the reach of immunotherapy to metastatic and treatment-resistant cancers.

Media Contact:
Maggie Whitney
mwhitney@lifescicomms.com
203-957-1502

Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition




Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study

Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in patients with advanced myeloid cancers

RPT1G anti-tumor efficacy data in pre-clinical non-Hodgkin lymphoma models to be showcased

GAITHERSBURG, Md., Dec. 04, 2025 (GLOBE NEWSWIRE) — Remedy Plan Therapeutics (“Remedy Plan”), a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with hematological malignancies and solid tumors, today announced the results from the Company’s first-in-human Phase 1 healthy volunteer study of lead candidate RPT1G. The candidate was safe and well-tolerated with significant NAMPT target engagement in healthy adult participants. Full results will be presented at the upcoming 67^th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida.

RPT1G is a novel hyperbolic inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in cellular metabolism and a well-established oncology target. This Phase 1 randomized, placebo-controlled trial (NCT06667765) assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RPT1G. The study (n = 56) included both single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts to inform dose selection and target engagement. Key results are as follows (poster #5044):

• RPT1G was well tolerated by all SAD and MAD cohort participants with no Treatment Emergent Adverse Events (TEAEs) above Grade 2 and no serious adverse events.
  • There was no discontinuation due to TEAE.
• Favorable PK profile established, without observed RPT1G accumulation over the 5-day dosing regimen.
• Dose-proportional NAMPT inhibition versus placebo observed.
  • The magnitude of target engagement was greater than responses achieved in xenograft mouse models at efficacious doses, supporting a therapeutic level of NAMPT inhibition in human subjects.

“Establishing the safety, PK, and PD profile of RPT1G is a huge leap forward, scientifically and clinically,” said Michael Schelle, PhD, Chief Scientific Officer of Remedy Plan. “The ability of RPT1G to safely inhibit NAMPT in people is compelling validation of our therapeutic approach and the years of research and development we’ve dedicated to NAMPT inhibition. Thanks to all of the study participants and investigators who helped us achieve this important milestone.”

Remedy Plan will also present a Trial in Progress abstract (poster #5208) outlining the designs and objectives of its ongoing multi-center, open-label Phase 1 study of RPT1G in patients with relapsed/refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS) (NCT07107126). In a third presentation (poster #5080), the Company will highlight new pre-clinical data demonstrating the preliminary anti-tumor efficacy of RPT1G in cellular and xenograft models of non-Hodgkin lymphoma (NHL), including 83% tumor growth inhibition (p = 0.0012) in a mouse xenograft model of NHL originating from germinal center B cells.

“Reaching this stage with our RPT1G lead program is a transformative moment for our company,” said Greg Crimmins, PhD, Founder and CEO of Remedy Plan. “Our momentum stems from a novel scientific approach and our commitment to bringing impactful therapies to patients with cancer.”

Details for Remedy Plan poster presentations at the 2025 ASH Annual Meeting are as follows:

About RPT1G

RPT1G inhibits nicotinamide phosphoribosyltransferase (NAMPT) using a unique mechanism—hyperbolic inhibition—to selectively reduce NAD in malignant cells. RPT1G is in Phase 1 trials for R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndromes). A first-in-human study showed that RPT1G provides potent NAMPT inhibition that is well-tolerated, without the on-target toxicities that ended previous NAMPT programs. With the NAMPT enzyme dysregulated in many cancers, we believe RPT1G signals a new era of treatment.

About the Phase 1 Healthy Volunteer Study

RPT1G was determined to be safe and well-tolerated in a first-in-human, Phase 1, single-center, randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult participants (NCT06667765). 56 participants were enrolled in the study with 42 receiving RPT1G. All participants completed treatment as planned. There were no reports of treatment emergent adverse events (TEAE) above Grade 2, no serious adverse events, and no TEAE leading to drug discontinuation. Target engagement data indicated that RPT1G inhibits NAMPT in humans at doses predicted to be clinically meaningful in hematologic malignancies.

About Remedy Plan Therapeutics

Remedy Plan Therapeutics is a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with hematological malignancies and solid tumors. Our mission is to solve a decades-old medical-science puzzle: targeting NAD synthesis in cancer cells without damaging healthy cells. Our lead asset, RPT1G, is a novel, small-molecule NAMPT inhibitor designed for this purpose. Our team comprises experienced scientists, clinicians, and drug developers working together to bring hope to communities affected by these diseases. For more information on Remedy Plan, visit remedyplan.com and follow us on LinkedIn.

Media Contact
Dawn Fallon
New Dawn Communications LLC
Dfallon@newdawncomms.com
732-771-7808

Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing




Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) — Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV) Deciparticle^™ formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of oral everolimus (Afinitor^®). The data indicate that Sapu003 may offer improved tolerability while preserving the drug’s intrinsic metabolic profile and enabling more consistent systemic exposure.

IV Sapu003 Reduces GI Exposure to Everolimus by 67-Fold Compared With Oral Dosing

New tissue-distribution data show that Sapu003, delivered intravenously, eliminates the extreme gastrointestinal accumulation characteristic of oral everolimus. After oral dosing, everolimus reaches 2,448× plasma levels in the stomach, 750× plasma in the small intestine, and 323× plasma in the large intestine, confirming that the gut is the dominant exposure site for the oral formulation.

In contrast, IV Sapu003 demonstrates only 36–48× plasma levels across the same GI tissues, representing a 67-fold reduction in stomach exposure, a 15.7-fold reduction in small-intestinal exposure, and a 7.4-fold reduction in large-intestinal exposure.

These findings provide a clear mechanistic explanation for the well-documented GI toxicity of oral everolimus—including stomatitis, mucositis, abdominal discomfort, and diarrhea.

Presentation information: PS4-06-05. Sapu003: Everolimus for Injection — Pharmacokinetic Rationale for Phase I Evaluation in HR⁺/HER2⁻ Metastatic Breast Cancer.

Potential for Improved Clinical Tolerability and Antitumor Potency

By bypassing the gastrointestinal tract and delivering the drug directly into circulation, Sapu003:

• Avoids the high local GI concentrations associated with oral toxicity
• Produces more consistent systemic exposure
• Enhances drug penetration into tumor-relevant tissues

These PK advantages complement previously reported efficacy findings in which Sapu003 achieved 97–98% tumor inhibition in glycolysis-addicted xenograft while outperforming paclitaxel.

Management Commentary
“The fundamental challenge with oral everolimus is that the majority of the drug ends up in the gut, leading directly to the GI toxicity that limits its use,” said Dr. Cynthia Lee, VP of R&D. “These new data show that IV Sapu003 avoids that problem entirely. By reducing GI accumulation by up to 67-fold, Sapu003 has the potential to offer a far more tolerable and clinically versatile version of everolimus.”

About Sapu003
Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano’s proprietary Deciparticle^™ technology. It is designed to overcome the poor bioavailability, intestinal toxicity, and variable patient exposure seen with oral everolimus while enabling reliable, predictable weekly IV dosing.

About the Deciparticle^™ Platform
The Deciparticle^™ platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as uniform, sub-20 nm nanoparticles for intravenous administration. The platform improves systemic exposure, reduces GI deposition, and supports precision delivery while maintaining manufacturability at clinical scale.

About Sapu Nano
Sapu Nano is a clinical-stage biotechnology company developing Deciparticle^™ nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based therapeutics. The company operates an integrated ISO-5 cGMP manufacturing facility supporting rapid progression from formulation to clinical trial supply.

For more information, visit www.sapunano.com.

Investor & Media Contact
Sapu Nano (US) LLC
Investor Relations
ir@sapubio.com

Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity




Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity

• Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors
• Matthew Baker appointed as CEO
• Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology

UTRECHT, the Netherlands – 4 December 2025 (08:30 CET). Laigo Bio, a company pioneering novel and highly differentiated therapies using its proprietary SureTAC™ precision membrane protein degradation platform, has successfully raised €11.5 million in a seed financing. The company will use the proceeds to advance its SureTAC™ oncology programs towards clinical development, and to accelerate discovery and development of its three SureTAC™ immunology candidate therapeutic programs for selected autoimmune and immunology indications and graft rejection.

Laigo Bio also announces the appointment of Dr Matthew Baker, the current acting Chief Executive Officer, as its CEO. Dr Baker is an accomplished serial biotech executive, with more than two decades of experience in inflammatory and oncology drug development, including previous roles as CEO at NeoPhore Ltd., non-executive director at Oxford Genetics, CSO at Abzena and CEO and CSO at Antitope Ltd, amongst several other senior positions. He is also a non-executive director at Fusion Antibodies, a leading CRO providing antibody development services.

“This seed funding is a strong endorsement of both the scientific foundation and the unique potential of our approach enabling selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases,” said Dr Matthew Baker, Chief Executive Officer of Laigo Bio. “With these resources, we are well positioned to initiate discovery efforts in auto-immunity and to advance our oncology programs through preclinical development. Our team remains focused on achieving key preclinical milestones and progressing our first-in-class lead programs toward early clinical evaluation, to deliver transformative therapies for patients.”

Surface Removal Targeting Chimeras (SureTAC™), developed by Prof Madelon Maurice’s laboratory at the UMC Utrecht, are proprietary therapeutic candidates for targeted degradation of membrane proteins, that have been validated as disease drivers but have eluded drug discovery, and were long considered “undruggable”. Developed by Laigo Bio, SureTAC™ are bispecific antibody molecules that induce degradation by bringing the cell surface target protein into close proximity with a surface E3 ligase enzyme, resulting in highly selective and deep inhibition of disease pathways in disease tissues.

In its oncology programs aimed at the immune checkpoint PD-L1 and VEGF, and a hard-to-drug Wnt pathway receptor, Laigo Bio has shown that its SureTAC™ degradation technology results in remarkable in vivo and in vitro efficacy. SureTACs show a high degree of selectivity for targeting diseased tissue, resulting in improved toxicity and safety. Laigo Bio intends to advance its oncology programs internally until completion of preclinical studies before collaborating with pharmaceutical partners to bring them into the clinic.

The funding round was co-led by Kurma Partners and Curie Capital. The other investors were Argobio Studio, Angelini Ventures (the venture capital arm of Angelini Industries, which is investing $300 million across a biotech and digital health portfolio in North-America and Europe), Eurazeo (a leading European investment group managing €36.8 billion across private equity, debt, real estate, and infrastructure), the Oncode Bridge Fund, ROM Utrecht region (a regional investor backed by the European Regional Development Fund), and UK-based Cancer Research Horizons, the translation subsidiary of the world’s largest charitable funder of cancer research, Cancer Research UK.

Laigo Bio was founded by the Oncode Institute, together with the Oncode Bridge Fund, and Argobio Studio, an international biotech start-up studio launched by Kurma Partners, BPI France and Angelini Ventures, key players in financing innovation in healthcare.

“Kurma is excited to support a company with such a promising technology platform targeting disease pathways that have long been deemed undruggable,” said Thierry Laugel, Chairman of the Management Board of Argobio and Managing Partner at Kurma Partners.

“Curie Capital is proud to support development of Laigo Bio’s SureTac™ unique platform technology because of its promise in addressing very specific therapeutic targets in diseases with high unmet medical need,” said Mariëtte Roesink, Managing Partner of Curie Capital.

Argobio Studio (www.argobiostudio.com) is the launch platform for Europe’s best medicinal science. They are operational venture builders dedicated to turning cutting-edge science into globally competitive companies pioneering breakthrough therapeutics for patients around the world. Argobio reduces execution risk by co-founding, investing, and embedding its experienced collaborative team to accelerate development with industrial rigor and speed toward value-creating milestones.

Oncode Institute (www.oncodeinstitute.nl), is a Dutch cancer research and innovation organisation dedicated to accelerating breakthroughs in cancer research and translating them into impactful diagnostics and treatments. We bring together 62 leading researchers and their teams from 13 partner institutes to pursue cutting-edge, high-risk, high-gain research. Through an integrated approach that bridges discovery, clinical practice, and market needs, Oncode Institute drives the transformation of innovations into tangible benefits for patients. We foster collaboration and drive valorization to maximize impact – advancing science, improving health outcomes, and contributing to economic value. Founded on the pillars of science, collaboration, and valorization, Oncode Institute is committed to outsmarting cancer and impacting lives.

Oncode Bridge Fund: The Oncode Oncology Bridge Fund provides early-stage financing to help the creation and growth of new enterprises based on the science of Oncode Investigators. The Bridge Fund aims to accelerate the translation of innovative cancer research of the Oncode labs into treatment options, diagnostic methods and research tools that benefit patients and society as a whole.

Kurma Partners (www.kurmapartners.com) – Founded in Paris in 2009, Kurma Partners has become a key player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from their inception and to finance their growth, across the spectrum of the healthcare sector through its various franchises. These have grown with successive funds in early-stage biotechnology (Biofunds I, II, III and IV), digital health and early-stage diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and, more recently, growth capital (Kurma Growth Opportunities Fund). Kurma’s teams, with a total of 25 people and 10 partners, are based in two offices, in Paris and Munich. They are deeply involved in the European ecosystem and have built up a solid network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry and fellow investors. Kurma Partners is part of the Eurazeo group.

Curie Capital (www.curiecapital.nl) – Founded in 2018 and based in Amsterdam, Curie Capital is a Life Sciences focused venture capital firm specialized in Seed and Series A stage biotechnology, pharmaceutical and medical Technology companies. The fund team actively uses its deep scientific knowledge, business experience and extensive global expert network to select and support its portfolio companies. Curie Capital invests in first-in-class and best-in-class solutions with the aim to make a positive impact on patients and healthcare.

Laigo Bio (www.laigobio.com), an early stage biotech company based in the Netherlands, is the first company to leverage E3 ligase internalization for the selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTAC™ platform creates bispecific antibodies that target the optimal pair of E3 ligase and disease-causing target to stimulate ubiquitination and lysosomal degradation of the target protein with a high degree of specificity. Degradation of the target protein achieves deeper inhibition of disease pathways, while sparing the desirable functions of the target cell.

For more information please contact:

Attachment

• 20251204 LaigoBio funding round press release (final)

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates




Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates

• New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD
• Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster session at ASN kidney week, the world’s premier nephrology meeting

• Successful completion of private placement supported by existing and new shareholders raising EUR 5.1 million; extends cash runway well into Q3 2026, providing financial runway and flexibility to realize strategic partnership
• Management to host conference call today at 3:00 pm CET (9:00 am EST)

Halle (Saale) / Munich, Germany, December 4, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced financial results for the nine-month period ended September 30, 2025, and provided a corporate update.

“The third quarter of 2025 and year to date have been marked by continued advancements towards realizing the full potential of varoglutamstat, including successfully completing a capital raise that provides us with financial runway and flexibility to advance our strategic objectives,” said Frank Weber, MD, CEO of Vivoryon. “Our recent analyses of VIVIAD/VIVA-MIND data continue to underscore the unique potential of varoglutamstat to meaningfully improve kidney function in patients with diabetes. A new analysis was conducted across patients with different eGFR baseline levels, which indicate different degrees of kidney function impairment, to evaluate how patients with impaired kidney function respond to varoglutamstat. Here, we saw a consistent and pronounced treatment effect across all patients and, importantly, we also saw this effect in patients with more impaired kidney function, as indicated by low baseline eGFRs. These results give us further confidence in our plan to advance varoglutamstat into a Phase 2b study in stage 3b/4 diabetic kidney disease.” He concluded, “Building on the beneficial effects on inflammation and fibrosis that we are observing with varoglutamstat, we see potential for this promising drug class to be relevant across a broader range of immune-mediated diseases. Here, our core expertise and differentiated platform of oral small-molecule QPCT/L inhibitors allow us to selectively explore additional development and partnership opportunities alongside our primary focus of advancing the DKD program.”

Q3 2025 and Post-Period Updates

Varoglutamstat Clinical Program

Vivoryon’s varoglutamstat Phase 2 program has shown highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studies. The Company is planning to confirm the previously reported compelling data from its two independent Phase 2 studies, VIVIAD and VIVA-MIND, by conducting a dedicated Phase 2b clinical study in patients with diabetic kidney disease (DKD) stage 3b/4. Initiation of the Phase 2b and all future studies is subject to additional funding and/or partnership, which Vivoryon continues to actively explore.

VIVIAD study data shows consistent treatment effect across eGFR levels in the lower eGFR percentiles

• New analysis of pooled data from Vivoryon’s varoglutamstat Phase 2 program revealed a consistent treatment effect in both the total population and in patients with diabetes.
• In patients with diabetes within the lower eGFR percentiles (50%/ 33.3%/ 25%/ 20%), mean eGFR baseline levels ranged from 65-56 mL/min/1.73m² and the treatment effect was in the range of 5.3-7.7 mL/min/1.73m²/year.
• These results further support Vivoryon’s rationale for a dedicated Phase 2b clinical study in patients with advanced DKD stage 3b/4.

VIVIAD study data presented at ASN

• On November 6, 2025, the Company presented a late-breaking poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial”, at the American Society of Nephrology (ASN) Kidney Week 2025, the world’s premier nephrology meeting.
• The poster featured VIVIAD Phase 2 clinical study data underscoring varoglutamstat’s unique ability to stabilize and even improve kidney function, as measured by eGFR values and highlighted further analyses of total population data from the VIVIAD study, evaluating the correlation of pE-CCL2 levels and eGFR slope on an individual participant level, which revealed a statistically significant correlation between the change from baseline in pE-CCL2 serum levels at week 48 and the eGFR slope over time. Specifically, a decrease in pE-CCL2 was significantly correlated with a positive (improved) eGFR slope.

Corporate Development Updates

• Following her temporary partial leave of absence to attend to a serious family health matter, reported by Vivoryon on September 4, 2025, Anne Doering will be stepping down as the Company’s CFO in December 2025. Marcus Irsfeld, an experienced finance executive with deep life sciences expertise, who has been working with Vivoryon as a strategic consultant since December 2024 and has assumed the role of acting CFO during Ms. Doering’s leave of absence, will succeed Ms. Doering as Vivoryon’s permanent CFO. Mr. Irsfeld is expected to stand for election as executive member of the Company’s Board at the 2026 Annual General Meeting.
• On October 6, 2025, Vivoryon successfully completed a private placement raising EUR 5.1 million by issuing 3,380,500 new shares at a purchase price of EUR 1.50 per new share. The placement was supported by existing and new shareholders and the capital raised extends the Company’s cash runway well into Q3 2026, with proceeds providing the financial runway and flexibility to realize strategic partnership for varoglutamstat in chronic kidney disease.

Financial Results for the Nine Months Ended September 30, 2025

Revenues were zero in the nine months ended September 30, 2025, as well as in the nine months ended September 30, 2024.

Research and development expenses decreased by EUR 8.9 million to EUR 3.7 million in the nine months ended September 30, 2025, compared to EUR 12.6 million in the nine months ended September 30, 2024. This reduction was largely attributable to a decrease in clinical development costs of EUR 7.2 million from the VIVIAD and VIVA-MIND studies and a reduction in production costs of EUR 1.2 million. R&D expenses in the reporting period mainly occurred for kidney-related research.

General and administrative expenses were EUR 4.0 million in the nine months ended September 30, 2025, compared to EUR 4.9 million in the nine months ended September 30, 2024. The decrease was largely attributable to lower personnel costs due to a decrease in non-cash effective share-based payments.

Net loss for the nine months ended September 30, 2025, was EUR 7.6 million, compared to EUR 17.1 million for the nine months ended September 30, 2024.

The Company held EUR 2.5 million in cash and cash equivalents as of September 30, 2025, compared to EUR 9.4 million as of December 31, 2024.

Outlook & Financial Guidance
Including the proceeds from the private placement completed in October 2025, the Company expects, based on its most recent financial and business plan, that its existing cash and cash equivalents will be sufficient to fund its operating plans well into Q3 2026, subject to the occurrence of unforeseen circumstances and without taking into account any funds possibly raised under the SEPA as well as other potential additional financing transactions, if any. This guidance is in line with the cash runway update published on October 6, 2025.
This cash runway guidance reflects an overall reduction in cash utilization including the conclusion of the VIVIAD and VIVA-MIND studies while prudently investing in preparing to execute on the Company’s kidney disease strategy. The initiation of the Phase 2b DKD study and all future studies is subject to further additional funding and/or partnership, which the Company continues to actively explore.
The viability of the Company’s business beyond its current guidance is dependent on its ability to raise additional funds to finance its operations which also depends on the success of its research and development activities such as those focusing on exploring opportunities in kidney disease.
The Company expects to have continuing operating losses for the foreseeable future and the need to raise additional capital to finance its future operations. The Company has concluded that the ability to continue as a going concern in the financial year 2026, as stated in the Company‘s Annual Report 2024 published on April 29, 2025, depends on the ability to generate additional funding. As such the Company has concluded that a material uncertainty exists that may cast significant doubt about its ability to continue as a going concern.
Please refer to the Company’s Annual Report 2024 for further information.

Conference Call and Webcast
Vivoryon will host a conference call and webcast today, December 4, 2025, at 3:00 pm CET (9:00 am EST). A Q&A session will follow the presentation of the third quarter 2025 results.
A live webcast and slides will be made available at: https://www.vivoryon.com/news-and-events/presentations-webcasts/

To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
https://register-conf.media-server.com/register/BI375e056b91ee4184ab17c7212371dfda

It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.

Approximately one day after the call, a slide-synchronized audio replay of the conference will be available on: https://www.vivoryon.com/news-and-events/presentations-webcasts/

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu

Attachment

• 20251204_VVY_3Q 2025

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update




Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, December 4, 2025 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.

“We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stroke recovery,” said Tim Dyer, CEO of Addex.

Operating Highlights: 

• Continued advancing GABAB PAM chronic cough candidate through preclinical development
• Advancing the preparation of dipraglurant for clinical studies in post-stroke recovery

Key Q3 2025 Financial Data

Financial Summary:

Income decreased by CHF 0.3 million during the nine-month period ended September 30, 2025, compared to the same period ended September 30, 2024, primarily due to the completion of the R&D collaboration phase of our agreement with Indivior. During the third quarter 2025 income primarily consisted of the reinvoicing of patent-maintenance costs associated with the patents licensed to Indivior pursuant to the licensing and research agreement entered into in 2018.

R&D expenses decreased by CHF 0.2 million during the nine-month period ended September 30, 2025, compared to the same period ended September 30, 2024, primarily due to lower GABAB PAM outsourced R&D expenses related to our R&D collaboration agreement with Indivior, since the research phase has been completed. During the third quarter of 2025, R&D expenses remained stable at CHF 0.2 million compared to the third quarter of 2024 and primarily related to outsourced expenses for our GABAB PAM chronic cough clinical candidate and the patent maintenance and registration costs.

G&A expenses decreased by CHF 0.4 million during the nine-month period ended September 30, 2025, compared to the same period ended September 30, 2024, primarily due to reduced professional fees. During the third quarter of 2025, G&A expenses remained stable at CHF 0.5 million compared to the third quarter of 2024 and primarily related to professional fees.

The net result decreased by CHF 13.2 million during the nine-month period ended September 30, 2025, compared to the same period ended September 30, 2024, primarily due to gross proceeds of CHF 14.0 million from the sale of a part of our business executed on April 2, 2024, and recognized as discontinued operations. During the same period ended September 30, 2025, the net loss from continuing operations increased by CHF 1.3 million primarily due to an increased share of loss from the investment in Neurosterix US Holdings LLC accounted for using the equity method since April 2, 2024. During the third quarter of 2025, the net result remained stable around CHF 1.5 million, including the share of loss of CHF 0.9 million from Neurosterix US Holdings LLC accounted for using the equity method.

Basic and diluted loss per share amounted to CHF 0.05 per share for the nine-month period ended September 30, 2025, compared to a basic and diluted profit per share of CHF 0.08 for the same period ended September 30, 2024. For the third quarter of 2025, the basis and diluted net loss per share decreased to CHF 0.01 compared to CHF 0.02 for the third quarter of 2024.

Cash and cash equivalents decreased to CHF 2.2 million at September 30, 2025, compared to CHF 3.3 million at September 30, 2024. The decrease of CHF 1.1 million between September 30, 2025, and September 30, 2024, is primarily due to operating activities.

Q3 2025 Consolidated Financial Statements:
The Q3 2025 financial report can be found on the Company’s website in the investor/download section here.

Conference Call Details:
A conference call will be held today, on December 4, 2025, at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science, will deliver a brief presentation followed by a Q&A session.

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link : Registration webcast

Conference call registration link : Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com
  
Contacts: 

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026




Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules

Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors will propose the following changes to shareholders for approval at the next Annual General Meeting on April 15, 2026: 

• Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election.
• The Board of Directors will propose the nomination of Matthias Gillner, Vice-Chairman of the Board, as the new Chairman.
• Gitte Pugholm Aabo will be proposed as a new independent member of the Board of Directors.

Gitte Pugholm Aabo was President and CEO of GN Store Nord’s Hearing Business from 2019 to 2023. Prior to that, she held various roles at LEO Pharma, Denmark, from 1992 to 2019, including EVP of Finance and IT before being appointed President and CEO in 2008. Over the past ten years, Gitte has served as a Board Member or Chair in various foundations and companies in Denmark and Sweden. She holds an MBA, a Graduate Diploma in Business Administration, and a Bachelor in Economics from Niels Brock Copenhagen Business College in Denmark.
With her strong financial background and CFO experience, Gitte is highly qualified to serve as a financial expert on the Board and would be well suited for membership in the Audit Committee.

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment

• 251204_Tecan PR_BoD_EN.pdf

Bestselling Author and Entrepreneur Dr. Reza Zahedi Expands into U.S. Market, Aiming to Build a Leading Real Estate and Media Portfolio




Bestselling Author and Entrepreneur Dr. Reza Zahedi Expands into U.S. Market, Aiming to Build a Leading Real Estate and Media Portfolio

Leadtainment founder and USA Today bestselling author announces bold U.S. expansion strategy, aiming to build a multi-million-dollar portfolio and deepen ties with key brokers, investors, and media partners.

Photo Courtesy of: Dr. Reza Zahedi

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — Dr. Reza Zahedi, USA Today bestselling author, civil engineer, and founder & CEO of Leadtainment, has announced an ambitious expansion of his business operations into the United States. The move marks a pivotal next phase in his global growth strategy, uniting his real estate, media, and thought-leadership ventures under a cohesive vision for international impact.

Building on a strong foundation in Germany and Europe, Dr. Zahedi and his team are now establishing a significant U.S. presence, focusing on creating a robust portfolio of commercial and multifamily real estate assets over the next five years. The initiative reflects his commitment to developing value-added properties that combine strategic renovation, operational excellence, and sustainable long-term performance.

“Our vision is to build a portfolio that reflects innovation, discipline, and value creation,” said Dr. Zahedi. “We see tremendous opportunity in combining engineering precision with entrepreneurial execution. It’s not just about growth, it’s about building something that endures across generations.”

To accelerate this strategy, Dr. Zahedi is forming partnerships with leading U.S. brokers, agents, and investment professionals to streamline acquisitions, unlock new market opportunities, and establish a powerful local network for ongoing operations.

The expansion also advances the global growth of Leadtainment. Dr. Zahedi’s platform integrates news, business, entertainment, and culture. With its reach now extending into North America, Leadtainment aims to bridge business insight with mainstream influence, amplifying Dr. Zahedi’s mission to inspire the next generation of leaders.

A civil engineer by training and an entrepreneur by passion, Dr. Zahedi brings a rare combination of analytical expertise and creative leadership. Specializing in identifying undervalued properties and unlocking their potential, he is among the few European-based investors successfully building a cross-continental portfolio in today’s competitive market.

“The U.S. has always represented innovation and possibility,” he added. “Our entry into this market is not just a business decision; it’s a statement of intent. We’re here to collaborate, build, and leave a lasting mark through integrity, strategy, and vision.”

Dr. Zahedi’s bestselling book, The Self-Made Maverick, continues to inspire entrepreneurs worldwide with lessons on resilience, risk-taking, and leadership.

About Dr. Reza Zahedi

Dr. Reza Zahedi is a global entrepreneur, author, and real-estate investor recognized for turning bold ideas into scalable ventures across media, consulting, and real estate. He is the founder & CEO of Leadtainment, a platform integrating business, culture, and innovation, and the author of The Self-Made Maverick, a USA Today and #1 Amazon bestseller. Featured in Forbes, CEOWORLD Magazine, International Business Times, and other leading outlets, Dr. Zahedi contributes regularly to Fast Company and SmartBrief on leadership, entrepreneurship, and business psychology.

Contact Information:

Contact Person’s Name: Dr. Reza Zahedi
Organization / Company: Zahedi Company Inc.
Company website: https://www.zahedi-co.com
Contact Email Address: expansion@zahedi-co.com
City, State / Province, Country, Zip Code: Beverly Hills, 90211 CA – USA

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60f81894-f339-47e8-a28a-f2120b43b984